Daiichi Sankyo Company, Limited

Mie University

Shiho Kozuma

Kensuke Nakamura

Junya Ichikawa

Ryuji Hashimoto

Hiroshi Shiku

Toshiaki Ohtsuka

Ichiro Watanabe

Makiko Nakayama

Naoya Shinozaki

Kento Tanaka

Yasushi Akahori

Ayaka Yatsu

Shinji Furuzono

Tohru Takahashi

Chigusa Yoshimura

Chikako Suzuki

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.

Anti-CD3 antibody and molecules comprising the antibody

Growing community of inventors

Tokyo, Japan

Shiho Kozuma